A randomized, double-blind, multiple-dose, placebo-controlled, dose escalation study with a 3-cohort parallel group design to investigate the tolerability and pharmacokinetics of albaconazole in healthy subjects

2013 ◽  
Vol 3 (1) ◽  
pp. 25-33 ◽  
Author(s):  
Albert J. Dietz ◽  
Joanna C. Barnard ◽  
Koen van Rossem
Keyword(s):  
Dose Escalation ◽  
Healthy Subjects ◽  
Multiple Dose ◽  
Dose Escalation Study ◽  
Double Blind ◽  
Group Design ◽  
Parallel Group Design ◽  
Parallel Group

A Comparison of Paroxetine, Imipramine and Placebo in Depressed Out-patients

1991 ◽  
Vol 159 (3) ◽  
pp. 394-398 ◽  
Author(s):  
G. C. Dunbar ◽  
J. B. Cohn ◽  
L. F. Fabre ◽  
J. P. Feighner ◽  
R. R. Fieve ◽  
...  
Keyword(s):  
Side Effects ◽  
Beneficial Effect ◽  
Anxiety Symptoms ◽  
Drop Out ◽  
Antidepressant Effect ◽  
Double Blind ◽  
Group Design ◽  
Parallel Group Design ◽  
Parallel Group ◽  
Antidepressant Efficacy

To compare the safety and antidepressant efficacy of paroxetine, imipramine, and placebo, data from six centres using the same protocol were pooled. A double-blind parallel-group design was used, with therapy lasting six weeks. From week 2 onwards, both the 240 paroxetine-treated and the 237 imipramine-treated patients were significantly different from the 240 placebo-treated patients, but no different from each other. Side-effects with paroxetine were less likely to lead to drop-out than with imipramine. Paroxetine had a possible earlier antidepressant effect than imipramine, and a possible earlier beneficial effect on anxiety symptoms associated with depression.

Sign in / Sign up

Export Citation Format

Share Document